New hope for tough prostate cancer? early trial launches

NCT ID NCT07493512

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the body. Participants receive the drug through a short IV infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: xaluritamig (AMG 509)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a very early Phase 1b study with only 40 participants, focused mainly on safety. It is too small and early to know if the drug will work or what side effects may emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Chris OBrien Lifehouse
RECRUITING

Camperdown, New South Wales, 2050, Australia
Monash Medical Centre
RECRUITING

Clayton, Victoria, 3168, Australia
Next Oncology - Dallas
RECRUITING

Irving, Texas, 75039, United States
Rocky Mountain Cancer Centers
RECRUITING

Denver, Colorado, 80218, United States
Sanford Oncology Clinic and Pharmacy
RECRUITING

Sioux Falls, South Dakota, 57104, United States
Sarah Cannon Research Institute Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
US Oncology Research Investigational Products Center
RECRUITING

Denver, Colorado, 80218, United States
United States Oncology Regulatory Affairs Corporate Office
RECRUITING

Denver, Colorado, 80218, United States
University of Pittsburgh Medical Center Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.